| Carly Melissa Murray, CCC-SLP | |
|
8448 Otis Dr, Arvada, CO 80003-1242 | |
| (303) 570-3181 | |
| Not Available |
| Full Name | Carly Melissa Murray |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 8448 Otis Dr, Arvada, Colorado |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104694892 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 17152761 (Colorado) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Carly Melissa Murray, CCC-SLP 10688 Milwaukee St, Northglenn, CO 80233-6114 Ph: () - | Carly Melissa Murray, CCC-SLP 8448 Otis Dr, Arvada, CO 80003-1242 Ph: (303) 570-3181 |
News Archive
New research carried out by forensic scientists at Anglia Ruskin University has shown that commonly-used emollients can pose a significant fire risk once they have dried on fabric such as clothing and bedding.
Elusys Therapeutics, Inc. today announced the U.S. Food and Drug Administration has accepted for filing and review its Biologics License Application for Anthim® (obiltoxaximab) for the treatment and prevention of inhalational anthrax, a top bioterror threat which was submitted on March 20, 2015. Anthim is a candidate for future acquisition into the Strategic National Stockpile, the U.S. government's repository of critical medical supplies for biowarfare preparedness.
Diabetes UK is urging healthcare professionals to be hypo-aware for Hypo-awareness Week (24th- 30th September). The charity wants to raise awareness about hypoglycemia and is encouraging healthcare professionals working in hospitals to look out for the signs of hypoglycemia and ensure those at high risk are given the necessary support.
The U.S. Food and Drug Administration today approved Brineura (cerliponase alfa) as a treatment for a specific form of Batten disease. Brineura is the first FDA-approved treatment to slow loss of walking ability in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase-1 (TPP1) deficiency.
A new study by researchers at Columbia University's Mailman School of Public Health found that the prevalence of past-month marijuana use among reproductive-aged women rose from 2.4 percent in 2002 to 3.9 percent in 2014, an increase of 62 percent.
› Verified 7 days ago
Kay, Lynn Swanson, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 7015 Nile Ct, Arvada, CO 80007 Phone: 303-503-3742 | |
Serena Laughren, CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 9713 W 57th Pl, Arvada, CO 80002 Phone: 720-722-0411 | |
Caitlin Page, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6616 Reed Ct, Arvada, CO 80003 Phone: 720-434-7777 | |
Mrs. Lisa Moore, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9353 Iron Mountain Way, Arvada, CO 80007 Phone: 937-313-5347 | |
Clg Solutions Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9090 Flora St, Arvada, CO 80005 Phone: 720-435-0350 | |
Speech Garden Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9713 W 57th Pl, Arvada, CO 80002 Phone: 720-722-0411 |